Feature
Anticoagulants
Dabigatran: how the drug company withheld important analyses
BMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g4670 (Published 23 July 2014) Cite this as: BMJ 2014;349:g4670Concerns over data in key dabigatran trial
Dabigatran, bleeding, and the regulators
The trouble with dabigatran
Related articles
- Paper Published: 01 July 2004; BMJ 329 doi:10.1136/bmj.329.7456.15
- Feature Published: 03 February 2016; BMJ 352 doi:10.1136/bmj.i575
- News Published: 19 October 2015; BMJ 351 doi:10.1136/bmj.h5557
- Feature Published: 23 July 2014; BMJ 349 doi:10.1136/bmj.g4747
- Research Published: 24 April 2015; BMJ 350 doi:10.1136/bmj.h1585
- Editor's Choice Published: 24 July 2014; BMJ 349 doi:10.1136/bmj.g4793
- Analysis Published: 23 July 2014; BMJ 349 doi:10.1136/bmj.g4517
- Editorial Published: 28 September 2016; BMJ 354 doi:10.1136/bmj.i5187
See more
- UK government’s nutrition advisers are paid by world’s largest food companies, BMJ analysis revealsBMJ September 11, 2024, 386 q1909; DOI: https://doi.org/10.1136/bmj.q1909
- Galleri promises to detect multiple cancers—but new evidence casts doubt on this much hyped blood testBMJ August 07, 2024, 386 q1706; DOI: https://doi.org/10.1136/bmj.q1706
- Cord blood banking: Experts raise concern over claims made for stem cell applicationsBMJ July 24, 2024, 386 q1581; DOI: https://doi.org/10.1136/bmj.q1581
- Revolving door: You are free to influence us “behind the scenes,” FDA tells staff leaving for industry jobsBMJ July 01, 2024, 386 q1418; DOI: https://doi.org/10.1136/bmj.q1418
- How an opioid giant deployed a playbook for moulding doctors’ mindsBMJ June 10, 2024, 385 q1208; DOI: https://doi.org/10.1136/bmj.q1208
Cited by...
- Periprocedural management of patients receiving novel oral anticoagulants
- Drug therapy in anticoagulation: which drug for which patient?
- Novel oral anticoagulants for atrial fibrillation
- Rivaroxaban: can we trust the evidence?
- Clinical utility of dabigatran in United Arab Emirates: A pharmacovigilance study
- To Monitor Dabigatran or Not: A Matter of Patient Safety
- Emergency reversal of dabigatran for emergency surgery
- Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study
- Bleeding complications of targeted oral anticoagulants: what is the risk?
- Novel oral anticoagulants: too good to be true?
- The trouble with dabigatran
- Boehringer Ingelheim withheld safety analyses on new anticoagulant, The BMJ investigation finds
- Concerns over data in key dabigatran trial